In the U.K. they will implement something interesting called value-based pricing. Basically, instead of paying for drugs, they will pay for the health outcomes related to these drugs, which is something completely different. You don't pay for the product, you pay for health outcomes. This is something new. This is something we need to follow.
On March 19th, 2013. See this statement in context.